Skip to main content
Premium Trial:

Request an Annual Quote

Delfi Diagnostics: David Morgenstern

David Morgenstern has been appointed as VP of clinical development at Delfi Diagnostics. He joins the cancer liquid biopsy company from Roche Diagnostics, where he was most recently head of clinical development for oncology and genetics. Prior to that, he led clinical affairs at pharmaceutical company Endocyte, and before that, he managed clinical studies at Merck. Morgenstern holds a PhD in microbiology and immunology from Indiana University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.